FDMT Form 3: VP Finance reports 45,662 shares, 27,700 options
4D Molecular Therapeutics (FDMT) filed a Form 3 reporting the initial holdings of its VP, Finance and Controller as of 09/30/2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
4D Molecular Therapeutics (FDMT) filed a Form 3 reporting the initial holdings of its VP, Finance and Controller as of 09/30/2025. The officer directly holds 45,662 shares of common stock. Derivative awards include stock options for 27,700 shares at $22.69 expiring 07/08/2034 and 7,056 shares at $4.14 expiring 03/05/2035. Restricted stock units total 13,850 and 3,528 shares, with vesting schedules beginning on June 20, 2025, subject to continued service.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Restricted Stock Units | -- | -- | -- |
| Holding | Restricted Stock Units | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Footnotes (5)
- F1. 25% of the shares subject to the stock option vest on the first anniversary measured from June 12, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
- F2. The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
- F3. The shares underlying the restricted stock unit award shall vest as to 25% of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.
- F4. Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock.
- F5. The shares underlying the restricted stock unit award shall vest as to 1/16th of the shares on June 20, 2025 and as to 1/16th of the underlying shares on each quarterly anniversary of such date thereafter, while the grantee remains a service provider to the Company.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did FDMT disclose in this Form 3?
What stock options were reported by FDMT's officer?
What RSUs are included in the filing for FDMT?
When do the RSUs begin vesting?
What is the officer’s role at FDMT?
AI-generated analysis. How Rhea-AI works. Not financial advice.